Evaluation of Cognitive State Using Neurosteer EEG System

Status Completed

Clinical Trial Summary

This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an auditory cognitive assessment tool and preforming tasks. EEG recordings will be analyzed using proprietary computational analyses.

Clinical Trial Description

One of the major problems in the prevention and treatment of neurological disorders, is the lack of cost effective and reliable tools to assess neurodegeneration on a large scale at a very early stage. Although current imaging methods give a clear image of the brain atrophy involved in neurodegenerative disorders, there are deficiencies prohibiting their usage for prevention-scanning of large high-risk population such as high price, long set-up time and the need for trained personnel to conduct the test. An objective tool to asses the level of cognitive decline is therefore needed. Such a tool may be used to determine the level of cognitive decline independent of personal interpretation and/or variance between clinicians and provide consistency in assessment across patients and between medical facilities. The Neurosteer system provides objective neurological biomarkers using a wearable easy-to-use affordable system. The system facilitate the capture and interpretation of EEG data with only a single patch of electrodes, attached on the subject's forehead. Neurosteer examination includes completing auditory tasks while measuring brain activity with the device. The data is analyzed using machine learning methods to produce biomarkers, enabling a report of the patient's activity in real time and offline. The examination is easy to preform and can be conducted in every clinic or in patients' homes. In this study, clinical staff will identify potential subjects and will examine the eligibility of subject according to inclusion and exclusion criteria. Patients (or legal guardian) will sign the Informed Consent Form (ICF). Research staff will set up an assessment session using Neurosteer system. In this session the patient will listen to the auditory assessment battery and perform tasks. Level of cognition will be assessed by Neurosteer technology and statistical analysis will be performed to validate the results. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04386902
Study type	Observational
Source	Neurosteer Ltd.
Contact
Status	Completed
Phase
Start date	September 19, 2019
Completion date	July 9, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03228446` - The Effects of Attentional Filter Training on Working Memory	N/A
Completed	`NCT04033419` - Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer	Phase 2
Terminated	`NCT05199142` - A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline	Phase 1
Terminated	`NCT03337282` - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Unknown status	`NCT00696514` - Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People	Phase 1
Completed	`NCT00110604` - The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing	N/A
Recruiting	`NCT06245005` - Preoperative Cognitive Reserve in Older Surgical Patients: A Feasibility Study
Recruiting	`NCT05014399` - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Active, not recruiting	`NCT05586750` - Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy	Phase 4
Recruiting	`NCT06070818` - Healthy Body & Mind Program for Older Adults Living With Osteoarthritis and Cognitive Decline	N/A
Completed	`NCT01669915` - A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline	N/A
Completed	`NCT02814526` - Exercise in Adults With Mild Memory Problems	N/A
Not yet recruiting	`NCT06252376` - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD	N/A
Recruiting	`NCT06318377` - Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals	N/A
Recruiting	`NCT03839784` - Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient
Completed	`NCT04537728` - My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices	N/A
Active, not recruiting	`NCT03370796` - Group Reminiscence Therapy for Elderly People With Cognitive Decline in Institutional Context	N/A
Completed	`NCT03775343` - Early Postoperative Cognitive Impairment in Elderly Patients Following Ocular Surgery
Active, not recruiting	`NCT04556305` - Lifestyle Physical Activity and Cognitive Training Interventions	N/A
Completed	`NCT04555941` - The Effects of Intermittent Theta Burst Stimulation in MCI and Early AD	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.